Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
about
Endocrine causes of nonalcoholic fatty liver diseaseThe current role of thiazolidinediones in diabetes management.Liver fat: a relevant target for dietary intervention? Summary of a Unilever workshopAnti-lipoapoptotic effects of Alisma orientalis extract on non-esterified fatty acid-induced HepG2 cells.An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia.Nonalcoholic Fatty Liver Disease in Canadian First Nations and Non-First Nations PatientsClinical guidelines of non-alcoholic fatty liver disease: A systematic review.Correlations of Hepatic Hemodynamics, Liver Function, and Fibrosis Markers in Nonalcoholic Fatty Liver Disease: Comparison with Chronic Hepatitis Related to Hepatitis C VirusAlbumin Binding Function: The Potential Earliest Indicator for Liver Function Damage.Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study.Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.Serum-inducible protein (IP)-10 is a disease progression-related marker for non-alcoholic fatty liver disease.A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis.Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus.A Noninvasive Score Model for Prediction of NASH in Patients with Chronic Hepatitis B and Nonalcoholic Fatty Liver DiseaseNonalcoholic fatty liver disease in Asia: emerging perspectives.Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease.Prevalence of nonalcoholic steatohepatitis in Japanese patients with morbid obesity undergoing bariatric surgery.Glycine prevents metabolic steatohepatitis in diabetic KK-Ay mice through modulation of hepatic innate immunity.Current and future pharmacological therapies for NAFLD/NASH.The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups.Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods.Animal models for analyzing metabolic syndrome-associated liver diseases.Human liver epigenetic alterations in non-alcoholic steatohepatitis are related to insulin action.Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus.Development of hepatocellular carcinoma in Japanese patients with biopsy-proven non-alcoholic fatty liver disease: Association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression.Insulin resistance increases the risk of incident type 2 diabetes mellitus in patients with non-alcoholic fatty liver disease.
P2860
Q26780254-E657A0B7-508E-4808-A754-D718A907A874Q30250347-FB10B8EF-9444-4263-8EB2-59A591F8D13BQ33791133-E7245D03-41C3-4C7A-AF09-E8B7952963B6Q36085347-729D46A9-8FFC-465B-A28F-FDE1EDFC586DQ36405031-87955172-4353-455A-9955-158799A5E5FAQ36996996-CA0E1014-B6B7-4A72-B6A3-F5755902A2A2Q37284519-17DDCCA1-9FE9-454F-ACC5-0DBF439B0BD0Q37286603-98F1DFDD-0F31-4C78-A7DC-53A89824753BQ37557655-3FC50FC3-C60B-451E-BD47-616169EB9B3AQ37590804-9EB9D976-CA8F-4FAD-8CBD-468DDD92EC6EQ38674014-4C11E0C4-0A19-48DA-B627-6290A90780FDQ38698155-3300245D-7E84-4227-8990-B704EA504EEFQ38732142-AEC3761F-03F1-49A6-86B3-4019A5DF1671Q38739234-B7FB8511-0099-4DCD-913A-4B421DDD8C6FQ38778064-00EA0B71-812A-4A83-B3BC-B6176C5A000EQ38872189-861E394B-0406-4297-8C98-2F3471697404Q38956717-9B5F6FA5-60AF-4BFA-9CAA-CB9FA39B6168Q40108180-0A15F22A-D2F4-4514-81B9-BE0210492778Q41445365-73E5CE68-A520-4E78-B0DC-B0613E5C33FAQ42499429-5647F944-E3C8-405D-B3FC-77011C5D66EFQ47778507-3B24B000-850C-4623-BC01-1A653D74AA2EQ48152092-AE8CADBC-E503-4043-A47B-7E627AE2EC4FQ48234623-A34DE124-16C1-4DD4-A5ED-80468FC10ABEQ50062580-761F7A19-F6B7-4B13-A367-F3797D93DB23Q51271391-144D6682-D881-4207-A9C0-329E6E4728BDQ53546193-7ABC37D7-EC0F-4BB1-A47A-1CB10D933CFCQ53551272-8BDADC6D-BA5E-4BDD-93C2-ADAF989039DCQ53736022-76D92215-44BC-416F-BF90-A092348B24BE
P2860
Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Evidence-based clinical practi ...... /nonalcoholic steatohepatitis.
@en
Evidence-based clinical practi ...... /nonalcoholic steatohepatitis.
@nl
type
label
Evidence-based clinical practi ...... /nonalcoholic steatohepatitis.
@en
Evidence-based clinical practi ...... /nonalcoholic steatohepatitis.
@nl
prefLabel
Evidence-based clinical practi ...... /nonalcoholic steatohepatitis.
@en
Evidence-based clinical practi ...... /nonalcoholic steatohepatitis.
@nl
P2093
P2860
P1476
Evidence-based clinical practi ...... /nonalcoholic steatohepatitis.
@en
P2093
Atsushi Nakajima
Etsuko Hashimoto
Goshi Shiota
Hirofumi Uto
Hirohito Tsubouchi
Isao Sakaida
Japan Society of Hepatology
Japanese Society of Gastroenterology
Katsutoshi Tokushige
Kenichi Ikejima
P2860
P304
P356
10.1007/S00535-015-1050-7
P577
2015-02-24T00:00:00Z